Overexpression of γ-Sarcoglycan Induces Severe Muscular Dystrophy

This publication has 27 references indexed in Scilit:

• Clinical Protocol: Phase I Clinical Trial Utilizing Gene Therapy for Limb Girdle Muscular Dystrophy: alpha-, beta-, gamma-, or delta-Sarcoglycan Gene Delivered with Intramuscular Instillations of Adeno-Associated Vectors
  Human Gene Therapy, 2000
• Rescue of Skeletal Muscles of γ-Sarcoglycan- Deficient Mice with Adeno-Associated Virus-Mediated Gene Transfer
  Molecular Therapy, 2000
• Functional Rescue of the Sarcoglycan Complex in the BIO 14.6 Hamster Using δ-Sarcoglycan Gene Transfer
  Molecular Cell, 1998
• Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo.
  Journal of Clinical Investigation, 1997
• Efficient muscle-specific transgene expression after adenovirus-mediated gene transfer in mice using a 1.35 kb muscle creatine kinase promoter/enhancer
  Gene Therapy, 1997
• β–sarcoglycan: characterization and role in limb–girdle muscular dystrophy linked to 4q12
  Nature Genetics, 1995
• β–sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex
  Nature Genetics, 1995
• Deficiency of dystrophin-associated proteins in Duchenne muscular dystrophy patients lacking COOH-terminal domains of dystrophin.
  Journal of Clinical Investigation, 1993
• MdxTransgenic Mouse: Restoration of Recombinant Dystrophin to the Dystrophic Muscle
  Human Gene Therapy, 1993
• Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy
  Cell, 1988